Sterling Capital Management
AXSM icon

Sterling Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Sterling Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.3K Sell
99
-186
-65% -$40.5K ﹤0.01% 2241
2026
Q2 		$69.8K Buy
285
+16
+6% +$3.47K ﹤0.01% 1496
2026
Q1 		$45.5K Buy
269
+1
+0.4% +$173 ﹤0.01% 1678
2025
Q4 		$48.9K Buy
268
+170
+173% +$23.7K ﹤0.01% 1812
2025
Q3 		$11.9K Hold
98
– – ﹤0.01% 2393
2025
Q2 		$10.2K Buy
98
+60
+158% +$6.35K ﹤0.01% 2121
2025
Q1 		$4.43K Buy
38
+1
+3% +$114 ﹤0.01% 2231
2024
Q4 		$3.13K Hold
37
– – ﹤0.01% 2637
2024
Q3 		$3.32K Buy
+37
New +$3.23K ﹤0.01% 1940

Other funds holding AXSM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Alethea Capital Management
Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return

Sterling Capital Management's AXSM Position: Q3 2026 in Review

Sterling Capital Management reduced its Axsome Therapeutics (AXSM) stake by 65% in Q3 2026, selling an estimated $40.5K and leaving 99 shares worth $18.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

Sterling Capital Management first reported a position in AXSM in Q3 2024 and has held it in 9 quarters since. The position peaked at $69.8K in Q2 2026. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Sterling Capital Management held 99 shares of Axsome Therapeutics worth $18.3K as of Q3 2026.
  • Sterling Capital Management sold 186 Axsome Therapeutics shares in Q3 2026, an estimated $40.5K.
  • Axsome Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2241 holding.
  • Sterling Capital Management first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • Sterling Capital Management's Axsome Therapeutics position peaked at $69.8K in Q2 2026.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.